“The Sky’s The Limit” For 3-D Printed Medical Devices, FDA Says
This article was originally published in The Pink Sheet Daily
In an interview, staff in CDRH’s Office of Science and Engineering Laboratories discuss the center’s research studies on 3-D printers used to manufacture medical devices and describe the challenges and opportunities that lie ahead.
You may also be interested in...
CDRH Director Jeffrey Shuren discussed the device center’s two-year strategic priorities with “The Gray Sheet.” The center plans to rebalance pre-market and post-market data collection, when appropriate, and improve the processes for starting up clinical trials in the U.S.
In a long-awaited final guidance, FDA affirmed its plan to practice enforcement discretion for most mobile medical apps, except those applications that present the same risks as conventional FDA-regulated devices. Some digital health stakeholders praised the guidance, while others wished FDA had waited.
The proposed surveillance program would test marketed blood glucose monitor systems to ensure they are performing at the level expected when they were cleared. It was met with support from FDA, device companies, academics and patient advocates.